| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/26/2008 | US20080153765 Inducing apoptosis in a bcl-6-expressing cell or a non-Hodgkin's lymphoma cell; nucleic acid molecule having a sequence corresponding to or complementary to accessible regions of bcl-6 mRNA, vectors, cells, |
| 06/26/2008 | US20080153764 Used in cells and transgenic animals for a variety of applications including producing and studying the effects of RNAi and microRNA mediated gene silencing. |
| 06/26/2008 | US20080153763 Contains only promoter and transcription sequence regions which minimizes immunogenicity because it does not contain extra sequences; resistant to digestion and relatively stable in serum and cells |
| 06/26/2008 | US20080153762 Removing the plants from the soil leaving the intact plants to cure for a period of at least 1 day, cutting up the cured plants, further drying the cut plants, to obtain dried plant material comprising the steroidal glycoside; used in the management of body weight or in the dietary control of obesity |
| 06/26/2008 | US20080153761 Compositions for protection against superficial vasodilator flush syndrome, and methods of use |
| 06/26/2008 | US20080153760 For increasing the mechanical strength of keratin fibers especially for reducing the phenomenon of breaking of the hair; C- beta -D-xylopyranoside-n-propan-2-one; 1-(C- alpha -D-galactopyranosyl)-2-hydroxypropane |
| 06/26/2008 | US20080153758 6-[Amino(4-chlorophenyl)-1-methyl-1H-imidazol-5-ylmethyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2R)-2-Amino-3-mercaptopropyl]amino]-3-methylpentyl]oxy]-1-oxo-3-phenylpropyl]amino]-4-(methylsulfonyl)-butanoic acid 1-methylethyl ester; exhibit potent activity agains |
| 06/26/2008 | US20080153757 Contains ascorbic acid, phenylalanine or tyrosine, ethyl lactate and a non-toxic zinc salt (zinc sulfate) |
| 06/26/2008 | US20080153741 mixture of small molecular weight nucleoprotein, deoxyoligonucleotide, DNA or RNA enzymatic or hydrolytic degradation product; obtained from fishes, yeast; easy transdermal absorption, improve hydrophilic, sebum level balance, preventing wrinkles; aging resistance |
| 06/26/2008 | US20080153739 Compositions and methods for treatment of hyperplasia |
| 06/26/2008 | US20080153738 Compositions and methods for treatment of hyperplasia |
| 06/26/2008 | US20080153167 In vivo amplification of neural progenitor cells |
| 06/26/2008 | US20080153112 identification of a predominant ligand of CD8+ T cells that are responsible eq for type 1 diabetes. That ligand is islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). Several CD8+ T cell-binding peptides from IGRP are identified, including the peptide comprising amino acids |
| 06/26/2008 | US20080153104 Gene Overexpressed in Cancer |
| 06/26/2008 | US20080152735 Herbal Extract Having Anti- Influenza Virus Activity and Preparation of Same |
| 06/26/2008 | US20080152732 Compositions and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis |
| 06/26/2008 | US20080152731 Compositions and method for hair loss prevention |
| 06/26/2008 | US20080152729 Plant extracts; Leishmaniasis and Trypanosomaisis infections |
| 06/26/2008 | US20080152726 Using polyunsaturated fatty acid and agent which adjust methionine metabolism such as vitamin b6, b12, folic acid; Parkinson's and Huntington's disease; antiepileptic agents; schizophrenia; antiepileptic agents; sleep disorders; antidepressants |
| 06/26/2008 | US20080152718 Bi-layer core isradipine; sustained release |
| 06/26/2008 | US20080152717 Enhanced bioavailability; solvent spray drying |
| 06/26/2008 | US20080152714 Pharmaceutical Formulations |
| 06/26/2008 | US20080152712 N-[1-oxo-3-methyl-4-((3-(3-fluorophenyl)-pyridin-6-yl)ethenyl)naphtho[2,3-c]furan-7-yl]butanamide bisulfate; administerable to unconscious patients suffering from acute coronary syndrome |
| 06/26/2008 | US20080152710 Co-beadlet of dha and rosemary and methods of use |
| 06/26/2008 | US20080152709 Clonidine composition and method of use |
| 06/26/2008 | US20080152708 Injectable, sucrose acetate isobutyrate solution easily formulated with therapeutic agents |
| 06/26/2008 | US20080152707 Solubilized CoQ-10 and Carnitine |
| 06/26/2008 | US20080152705 Corosolic Acid Formulation and Its Application for Weight-Loss Management and Blood Sugar Balance |
| 06/26/2008 | US20080152704 Gelatin capsules filled with an aqueous dispersion of lipophilic components and surfactants; antiemitic agents for chemotherapy and radiotherapy patients |
| 06/26/2008 | US20080152703 Epitopes formed by non-covalent association of conjugates |
| 06/26/2008 | US20080152702 Improved blood circulation lifetime of drug-carrying liposomes having a surface coating of releasable hydrophilic polymer covalently and reversibly linked to an phospholipid or polypeptide through a dithiobenzyl linkage |
| 06/26/2008 | US20080152700 Two nucleotides containing 5-methylcytosine, the first hybridizing to the promoter region of a c-Ha-ras gene and the second hybridizing to an oncogene; anticarcinogenic agents for melanomas, pancreatic, colon, breast, bladder, lung, leukemia, prostate, lymphoma, and ovarian cancers |
| 06/26/2008 | US20080152699 Method of treating menopausal women transdermally with testosterone |
| 06/26/2008 | US20080152698 Hydrogel |
| 06/26/2008 | US20080152695 Oral/buccal transmucosal delivery methods for electrolyte compositions including xylitol |
| 06/26/2008 | US20080152694 Devices, Systems and Methods for Ophthalmic Drug Delivery |
| 06/26/2008 | US20080152693 A dopamine agonist and a biodegradable polymer; preferably ropinirole and polylactic acid; side effect reduction; Parkinson's Disease, Attention Deficit Disorder, autism, Asperger's Syndrome, erectile dysfunction, restless leg syndrome, or hyperprolactinemia |
| 06/26/2008 | US20080152666 Apoptosis-inducing polypeptides |
| 06/26/2008 | US20080152661 Polyconjugates for In Vivo Delivery of Polynucleotides |
| 06/26/2008 | US20080152659 Using presence of deletion in complement Factor H-related 4 gene as evaluative tool in predicting aneurysm and vision defects |
| 06/26/2008 | US20080152654 COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
| 06/26/2008 | US20080152650 Methods and Compositions For Specifically Targeting Human Hepatocellular Carcinoma Cells |
| 06/26/2008 | US20080152643 Using modulators of toll-like receptor and/or uncooridinated protein activities as therapeutic agents in treatment of diabetes, multiple sclerosis, rheumatoid arthritis and addison's diseases |
| 06/26/2008 | US20080152642 Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof |
| 06/26/2008 | US20080152641 Inhibitors of Siderophore Biosynthesis in Fungi |
| 06/26/2008 | US20080152640 administering drugs comprising inhibitor of ATP-binding cassette transporters (ABC-transporter), such as verapamil or valspodar, for the treatment of arthritis; drug screening |
| 06/26/2008 | US20080152639 Using enzyme mixtures to control concentration of small leucine rich proteoglycans (SLRPs) and glycosaminoglycans in tissues and treat and prevent skin disorders |
| 06/26/2008 | US20080152633 Flavivirus Replicon Constructs for Tumor Therapy |
| 06/26/2008 | US20080152621 Antiviral nucleosides |
| 06/26/2008 | US20080152619 Hepatitis C virus inhibitors |
| 06/26/2008 | US20080152618 Using tumor necrosis factor superfamily of ligands as therapeutic tool in treatment and prevention of cell proliferative disorders |
| 06/26/2008 | US20080152616 Amphiphilic block copolymer and polymeric compostition comprising the same for drug delivery |
| 06/26/2008 | US20080152614 Method and kit for skin lesion prevention and/or protection |
| 06/26/2008 | US20080152597 Dermal penetration enhancers and drug delivery systems involving the same |
| 06/26/2008 | US20080152588 Metal Chelators and Methods of Their Use |
| 06/26/2008 | US20080152585 comprising a mixture of drugs having nanostructure particle sizes, surfactants and excipients or carriers |
| 06/26/2008 | US20080149097 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disordersB |
| 06/26/2008 | DE20122843U1 Fentanyl Zusammensetzung zur nasalen Anwendung Fentanyl composition for nasal administration |
| 06/26/2008 | DE102006062264A1 Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen Use of xanthohumol for preventing and / or combating liver disease |
| 06/26/2008 | DE102006062250A1 Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden Use of a composition of minerals and / or vitamins and optionally acetogenic and / or butyrogenic bacteria for oral or rectal administration for the treatment and prevention of abdominal discomfort |
| 06/26/2008 | DE102006062203A1 Substituierte 5H-Pyrimido[5,4-b]indole als Induktoren der Apoptose bei B-CLL Zellen Substituted 5H-pyrimido [5,4-b] indoles as inducers of apoptosis in B-CLL cells |
| 06/26/2008 | DE102006062120A1 Pharmazeutische Zusammensetzung zur Aknebehandlung A pharmaceutical composition for the treatment of acne |
| 06/26/2008 | DE102006062119A1 Arzneimittel zur Behandlung von Hauterkrankungen Drugs for the treatment of skin diseases |
| 06/26/2008 | DE102006062111A1 Zusammensetzung, insbesondere für das Blockieren von Kathetern Composition, in particular for blocking catheters |
| 06/26/2008 | DE102006061913A1 New amide compounds used for treatment of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy, has general formula |
| 06/26/2008 | DE102006060598A1 New tetrahydrobenzoisoxazole compounds are mitotic motor protein Eg5 modulators useful to treat and prevent cancer, and to treat e.g. monocyte leukemia, glioblastoma, colon carcinoma, myelotic leukemia and lymphatic leukemia |
| 06/26/2008 | CA2695613A1 Sulfonamide derivatives with therapeutic indications |
| 06/26/2008 | CA2690273A1 Use of prostaglandin ep4 agonist for treating gastrointestinal disorders |
| 06/26/2008 | CA2673841A1 Prophylactic or therapeutic agent for alopecia |
| 06/26/2008 | CA2673719A1 T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery |
| 06/26/2008 | CA2673717A1 Method for administration of pegylated liposomal doxorubicin |
| 06/26/2008 | CA2673591A1 Chemical compounds |
| 06/26/2008 | CA2673582A1 Pyridine benzamides and pyrazine benzamides used as pkd inhibitors |
| 06/26/2008 | CA2673566A1 Preparation and utility of ccr5 inhibitors |
| 06/26/2008 | CA2673564A1 Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer |
| 06/26/2008 | CA2673481A1 Combined effects of topiramate and ondansetron on alcohol consumption |
| 06/26/2008 | CA2673468A1 Indole derivatives as s1p1 receptor agonists |
| 06/26/2008 | CA2673454A1 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 06/26/2008 | CA2673451A1 Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
| 06/26/2008 | CA2673444A1 Polymorphs of a mglur5 receptor antagonist |
| 06/26/2008 | CA2673430A1 2-adamantyl-butyramide derivatives as selective 11.beta.-hsd1 inhibitors |
| 06/26/2008 | CA2673419A1 Pharmaceutical composition |
| 06/26/2008 | CA2673418A1 Pharmaceutical compound and composition |
| 06/26/2008 | CA2673417A1 Radioprotective benzimidazole compounds and related methods |
| 06/26/2008 | CA2673359A1 Cb1 receptor modulators |
| 06/26/2008 | CA2673358A1 Pyrazole derivatives as modulators of cannabinoid receptor |
| 06/26/2008 | CA2673356A1 Crth2 antagonists |
| 06/26/2008 | CA2673353A1 Aminopyrimidines useful as inhibitors of protein kinases |
| 06/26/2008 | CA2673336A1 Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use |
| 06/26/2008 | CA2673315A1 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 06/26/2008 | CA2673277A1 Indazolyl ester and amide derivatives for the treatment of glucocorticoid receptor mediated disorders |
| 06/26/2008 | CA2673219A1 O-substituted-dibenzyl urea-derivatives as trpv1 receptor antagonists |
| 06/26/2008 | CA2673214A1 New combination for use in the treatment of inflammatory disorders |
| 06/26/2008 | CA2673177A1 Modulators of cb1 receptors |
| 06/26/2008 | CA2673119A1 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors |
| 06/26/2008 | CA2673095A1 Indazole derivatives as kinase inhibitors for the treatment of cancer |
| 06/26/2008 | CA2673093A1 Non-nucleoside reverse transcriptase inhibitors |
| 06/26/2008 | CA2673040A1 Use of tri-substituted glycerol compounds for the treatment of hematological malignancies |
| 06/26/2008 | CA2672985A1 Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
| 06/26/2008 | CA2672984A1 Combination therapy for treating hepatitis c infections |